Ashfield Launches EmerGENE to Support Biotechs’ Commercialization Activities

Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries.

The first of its kind in the industry, EmerGENE has been built by a multidisciplinary team that delivers expert-led guidance and services to biotechs throughout their entire clinical to commercial journey.

Combining experts from Ashfield Health, Ashfield Engage, and Ashfield Advisory, EmerGENE aims to unlock the potential of cell and gene therapy, helping drug developers to bring transformational treatments to patients.

The experts at EmerGENE have supported five of the six current commercialized cell and gene therapy products on their journey to market. EmerGENE’s offering includes:

• Distribution and logistics
• Pre-clinical support
• Commercial and organizational strategies
• Market access and value
• Commercial team build-out and support
• Disease, platform and launch communications
• Medical information services
• Patient support programs

Ashfield Healthcare (Ashfield) is a division of UDG Healthcare. Operating across two divisions, Ashfield and Sharp, UDG provides outsourced services which enable over 300 healthcare companies from large pharmaceutical to small biotech to bring their products to market, supporting patients to access and adhere.

Ashfield partners with clients across Advisory, Healthcare Communications, Commercial, Patient Solutions and Medical Affairs to build creative, scalable and tailored health solutions to address their client’s challenges and deliver positive outcomes for patients.

Ashfield has more than 7,000 employees, operates in 28 countries, and delivers services in more than 50 countries across Europe, North America, South America and Asia. It works with more than 250 businesses, including all of the world’s top 25 pharmaceutical companies.

Takeaway: EmerGENE works to find the correct path in providing advice and executing solutions and ultimately realizing the potential of cell and gene therapies for patients and their families